Skip to main content

ADA/EASD Issue New Hyperglycemia Management Guidelines


April 19, 2012 — The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) have issued a joint position statement emphasizing patient-specific treatment of hyperglycemia in persons with type 2 diabetes. The new guidelinesare reported concurrently in the April 19 online edition of Diabetes Care and in Diabetologia.
"All guidelines are in a state of evolution based on new information, and the overall standard of care is updated every January," Vivian Fonseca, MD, ADA president of medicine and science, told Medscape Medical News in a telephone interview.
The last guidelines specific to management of hyperglycemia were published about 4-5 years ago, and more recent developments have been incorporated into the new guidelines."
The impetus underlying the new guidelines was the growing complexity and controversy surrounding contemporary glycemic management in persons with type 2 diabetes. Factors complicating management include the increasing number and variety of available pharmacotherapy, issues regarding potential adverse effects, and new uncertainties concerning the effects of intensive glycemic control on macrovascular complications.
Dr. Fonseca, who is also professor of medicine and endocrinology at Tulane University in New Orleans, Louisiana, explained that there has been a small change in what the optimal blood glucose goal should be. On the basis of findings from ACCORD (Action to Control Cardiovascular Risk in Diabetes study) and other studies, the ADA has set the HbA1c goal at 7% in general, but with some individualization.
"For patients with advanced cardiovascular disease, reduced life expectancy, and multiple medical problems, for example, the goal may be higher," Dr. Fonseca said. "For patients who are newly diagnosed and very motivated, the goal may be lower."
Another recent change underlying the new guidelines is the recognition that many people with diabetes will need multiple agents. For example, the dipeptidyl peptidase-4 (DPP4) inhibitors have become available since the last hyperglycemia guideline was published.
Patient-Centered Management
Rather than using clearly defined algorithms, the new guidelines are less prescriptive and more patient-centered. Recommendations are tailored to individual patient needs, preferences, and tolerances and are based on differences in age and disease course. Other factors affecting individualized treatment plans include specific symptoms, comorbid conditions, weight, race/ethnicity, sex, and lifestyle.
"We start with metformin, and if the patient is not meeting goal in 3 months, we change therapy based on patient-specific factors," said Dr. Fonseca, who was not involved in writing the new guidelines.
"There have been no good studies comparing all available treatment strategies, so we base the decision on individual factors such as willingness to self-inject, or need for weight loss. If that fails, we try another option. There is no clear-cut decision tree as there was in the previous hyperglycemia guideline, because this guideline is more patient-centric."
The position statement mandates diabetes education for all patients, to be administered to individuals or groups. The curriculum should highlight dietary intervention and the key role of increased physical activity and weight management, when appropriate, in an individual or group setting.
"The new guideline should actually be easier for physicians to implement because there is greater flexibility in management, offering a road map rather than a single path," Dr. Fonseca concluded. "The ADA guidelines in general are already fairly widely implemented, and we are seeing benefits from that. Over the past 10-15 years, HbA1c has been dropping, and over the past year, there has started to be a drop in rates of diabetes-related blindness, retinopathy, dialysis, and amputation. But there still remain a large number of patients with these outcomes, so we still have a ways to go."
Key Points
Key recommendations in the new ADA/EASD statement include the following:
  • Glycemic targets and treatments to lower glucose must be individualized according to specific patient characteristics.
  • The mainstay of any type 2 diabetes treatment program is still diet, exercise, and education.
  • Metformin is the preferred first-line drug, in the absence of contraindications.
  • Data are limited regarding use of agents other than metformin. A reasonable approach is combination therapy with 1 to 2 additional oral or injectable agents, with the goal of minimizing side effects to the extent possible.
  • To maintain glycemic control, many patients will ultimately need insulin monotherapy or in combination with other medications.
  • Whenever possible, the patient should participate in all treatment decisions, focusing on their preferences, needs, and values.
  • A major treatment goal must be comprehensive cardiovascular risk reduction.
Others Weigh in on the New Guidelines
In an accompanying editorial, Diabetes Care editor William Cefalu, MD, notes that some experts prefer an algorithm-based management plan offering consistent treatment guidelines, whereas others favor flexible treatment options based on specific pathophysiology.
"The most attractive aspect of the new position statement is that more than any other previously reported guidelines to date, it clearly emphasizes that 'one size clearly does not fit all'," Dr. Cefalu writes.
EASD President Andrew J.M. Boulton also commended the new guidelines for their patient-specific approach.
"The new guidelines were prepared using the best available evidence," Dr. Boulton said in a news release. "Diabetes is a condition which affects people in a multitude of ways: the new guidelines take a more holistic approach, focusing on treating the patient as an individual and understanding that treatments need to be 'made to measure,' an approach that will likely improve not only patient care, but also quality of life."
The statement authors report various financial disclosures with Abbott Diabetes Care, Amylin, Bayer, Becton Dickinson, Boehringer Ingelheim, Calibra, DexCom, Eli Lilly, Halozyme, Helmsley Trust, Hygieia, Johnson & Johnson, Medtronic, National Institutes of Health, Novo Nordisk, Roche, Sanofi, Takeda, Merck, AstraZeneca, Biodel Inc; Bristol-Myers Squibb, Diartis Pharmaceuticals Inc, F. Hoffmann-La Roche, Halozyme Therapeutics, Medtronic MiniMed, Pfizer Inc, TransPharma Medical Ltd, Poxel Pharma, Astra-BMS, GlaxoSmithKline, Novartis, Servier,Tolerx, Berlin-Chemie, Diartis, Intarcia Therapeutics, sanofi-aventis Pharma, Versartis, MSD, and/or Merck Serono. Dr. Fonseca states that he has no conflicts of interest regarding the new guidelines. He has been involved in research trials funded by Novo Nordisk, sanofi-aventis, Eli Lilly, Reata, Abbott, Mesoblast, Pan-American Laboratory, and Takeda. He has been a consultant for Takeda, Novo Nordisk, sanofi-aventis, Eli Lilly, Pan-American Laboratory, Daichi-Sankyo, Xoma, Astra Zeneca, Abbott, Bristol-Myers Squibb, and GlaxoSmithKline.

Comments

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...

Obama Renominates Tavenner to Be CMS Chief

President Barack Obama yesterday renominated Marilyn Tavenner, the acting administrator of the Centers for Medicare & Medicaid Services (CMS), to serve in that post without the caveat of "acting" attached to it. If the Senate approves her nomination, Tavenner will be the first confirmed, full-fledged CMS administrator since Mark McClellan, MD, PhD, stepped down from that position in October 2006, during the George W. Bush administration. Dr. McClellan's successors either were acting administrators or, in the case of Donald Berwick, MD, who was Tavenner's immediate predecessor, a recess appointment. As illustrated by Dr. Berwick's  CMS history , Senate confirmation can be tough to get when one party has enough votes to filibuster and otherwise stymie a nomination by an opposing party's president. That was the case when Obama nominated Dr. Berwick, whom Senate Republicans portrayed as an advocate of healthcare rationing, a characterization denied by t...

Secondary Prevention: Clinical Approaches to Managing the Higher-Risk Patient with Heart Disease

INCIDENCE/PREVALENCE/BURDENS ASSOCIATED WITH CARDIOVASCULAR DISEASE (CVD) The prevention of an initial and recurrent cardiovascular event and other complications, such as diabetes and kidney failure [also known as end-stage renal disease (ESRD) or chronic kidney disease (CKD) stage 5] is an important goal in patients with a history of CVD. Each year, approximately 185,000 Americans suffer a recurrent stroke, approximately 470,000 will have a recurrent coronary attack, and an estimated 325,000 will suffer a recurrent myocardial infarction. [1]  Secondary prevention strategies offer the opportunity to prevent further complications and improve outcomes by early detection and management of common comorbidities. The burden on public health and the costs associated with chronic illnesses such as CVD, CKD, and diabetes remain high. An estimated 82.6 million American adults (1 in 3) have 1 or more types of CVD. [1]  Heart failure is the fastest-growing clinical cardiac disease ...